Background: There is no consensus on the indications for stereotactic biopsy for brain stem masses in children. Objectives: We analyzed the results of stereotactic biopsy for brain stem masses in 106 consecutive children to define current indications for this surgery. Methods: We performed a retrospective review of inpatient summaries, stereotactic worksheets and radiological investigations of 106 consecutive patients, under the age of 18 years, who underwent CT-guided stereotactic biopsies for brain stem lesions between 1987 and 2008. Patients were divided into two eras: era I from 1987 to 1997 and era II from 1998 to 2008. Results: 91 children underwent a biopsy in era I, and 15 had the procedure in era II, this difference clearly indicating the impact of the availability of magnetic resonance imaging. There was no difference in the proportion of diffuse lesions biopsied in both eras. Astrocytoma was the most frequently diagnosed pathology in both eras accounting for nearly 90% of biopsies. Inflammatory masses were diagnosed in less than 10% of patients. There was no mortality or permanent morbidity. Mortality, on follow-up, in children with diffuse low- and high-grade astrocytoma was similar. Conclusions: CT-guided stereotactic biopsy for brain stem masses in children is safe and is presently indicated in ruling out an inflammatory pathology of an enhancing mass of the brain stem.

Keywords:
Brain stem, Children, Glioma, Stereotactic biopsy, Inflammatory mass
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.